Mode
Text Size
Log in / Sign up
N/A N=53 Randomized Supportive Care

Stress in Inflammatory Bowel Disease

Inflammatory Bowel Diseases · Psychological

Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Retention Rate — 23; 25; 19; 22 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Biofeedback Enhanced Treatment (Behavioral)
Age
Pediatric, Adult · 13+ yrs
Sex
All
Sponsor
Emory University
Primary completion
Jan 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Retention Rate
23; 25; 19; 22
PRIMARY
Client Satisfaction Questionnaire (CSQ-8) Scores Following Biofeedback Enhanced Treatment
28.02; 28.73
SECONDARY
Change in the Children's Depression Inventory 2 (CDI-2) at Six Weeks Compared to Baseline
-1.99; 0.00
SECONDARY
Change in the Children's Depression Inventory 2 (CDI-2) at 2 Months Post-treatment Compared to Baseline
-4.17
SECONDARY
Changes in the Behavior Assessment System for Children (BASC) Depression Parent Rating Scale at 6 Weeks
-3.64; 0.44
SECONDARY
Changes in the Behavior Assessment System for Children (BASC) Depression Parent Rating Scale at 2 Months After Completing Treatment Intervention
-4.60
SECONDARY
Changes in the Screen for Child Anxiety Related Disorders (SCARED) Scores at 6 Weeks (End of Treatment)
-5.05; -0.67; -1.87; -1.84
SECONDARY
Changes in Screen for Child Anxiety Related Disorders (SCARED) Scores in Both Groups at 2 Months After Completing Treatment
-4.28; -1.87
SECONDARY
Changes in the Children's Somatic Symptoms Inventory (CSSI) 7-item (GI Subscale) After Completion of Biofeedback Enhanced Treatment
-1.29; 0.56; -2.79; -0.12
SECONDARY
Changes in the Children's Somatic Symptoms Inventory- (CSSI) 7-item (GI Subscale) at 2 Months After Completion of Treatment Intervention
0.62; -0.01
SECONDARY
Change in Autonomic Reactivity at 6 Weeks (End of Treatment)
15.6; 16.74; -4.09; 16.02

Summary

This is a prospective, assessment-based study to examine the relationship between psychophysiological functioning and psychological symptoms in youth newly diagnosed with inflammatory bowel disease (IBD) compared to healthy controls.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with biopsy-confirmed IBD
  • Ages 13 through 18 years inclusive
  • English fluency for parent and child participants.
  • Accompanied by at least 1 parent/guardian who is willing to participate
  • Positive depression or anxiety symptom screen using the patient health questionnaire (PHQ-9) or Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Anxiety measures

Exclusion Criteria

  • Previous diagnosis of intellectual disability
  • Autism spectrum disorder.
  • Parent is unwilling to participate.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05202418). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search